Hanmi Pharm terminates development of Olita, “We’ll focus efforts on making global new drugs”

Published: 2018-04-16 17:01:59

Updated: 2018-04-16 17:01:59

Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) decided to terminate development of ‘Olita(generic name: olmutinib),’ a targeted therapy for lung cancer, and announced on the 13^th that the company has been in progress to make an agreement with the Ministry of Food and Drug Safety(MFDS) for the detailed approval procedure.

In regards to the development termination, Hanmi Pharm explained that the...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.